Harold Selick Sells 24,000 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director Harold Selick sold 24,000 shares of the company’s stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $105.00, for a total transaction of $2,520,000.00. Following the transaction, the director owned 60,845 shares of the company’s stock, valued at approximately $6,388,725. The trade was a 28.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Protagonist Therapeutics Price Performance

NASDAQ PTGX opened at $98.97 on Monday. The firm has a market capitalization of $6.32 billion, a price-to-earnings ratio of -48.28 and a beta of 2.23. The company’s fifty day moving average is $88.99 and its two-hundred day moving average is $82.68. Protagonist Therapeutics, Inc. has a 52-week low of $39.60 and a 52-week high of $105.69.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.16). The company had revenue of $7.44 million for the quarter, compared to analyst estimates of $14.92 million. Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.89%. As a group, sell-side analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PTGX. Farther Finance Advisors LLC boosted its holdings in Protagonist Therapeutics by 110.6% during the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after purchasing an additional 156 shares in the last quarter. Greenline Wealth Management LLC bought a new stake in Protagonist Therapeutics in the fourth quarter valued at $27,000. Salomon & Ludwin LLC acquired a new position in Protagonist Therapeutics during the third quarter worth $29,000. EverSource Wealth Advisors LLC raised its stake in Protagonist Therapeutics by 138.9% during the third quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock worth $36,000 after acquiring an additional 314 shares in the last quarter. Finally, Abich Financial Wealth Management LLC bought a new position in shares of Protagonist Therapeutics during the third quarter valued at $62,000. Institutional investors own 98.63% of the company’s stock.

More Protagonist Therapeutics News

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: One‑year Phase 3 data for ICOTYDE (icotrokinra) presented at the 2026 AAD meeting showed durable skin clearance and a favorable safety profile for a once‑daily oral IL‑23 receptor targeted peptide — a meaningful clinical validation for the company’s lead psoriasis program that supports longer‑term upside. Read More.
• Positive Sentiment: At least one analyst raised their price target (reported +11.65% to $114.50), and multiple firms have recently bumped targets or issued “buy/overweight” views — analyst optimism following the data can underpin further gains if commercial potential is reinforced. Read More.
• Neutral Sentiment: Industry and strategy commentary highlights the company’s peptide platform and pipeline potential; useful context for long‑term investors but not an immediate catalyst. Read More.
• Negative Sentiment: Clustered insider selling on March 26 from multiple executives (CFO Asif Ali, Director Harold Selick, and insider Arturo Md Molina) — roughly 63,765 shares disclosed across filings for approximately $6.7M in proceeds — created visible near‑term selling pressure and is being read negatively by the market. SEC filings and trade details here: Read More. and Read More.
• Negative Sentiment: Recent quarterly results (Feb. 25) showed an EPS and revenue miss (EPS -$0.69 vs. -$0.53 est.; revenue $7.4M vs. $14.9M est.), a reminder of continuing execution and commercialization risks for a clinical‑stage biotech. Read More.

Analyst Upgrades and Downgrades

Several equities analysts have commented on PTGX shares. The Goldman Sachs Group upped their price target on Protagonist Therapeutics from $65.00 to $95.00 and gave the company a “neutral” rating in a report on Tuesday, March 3rd. Barclays boosted their price objective on Protagonist Therapeutics from $113.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday, March 19th. Truist Financial upped their target price on Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Weiss Ratings cut Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, February 17th. Finally, Citizens Jmp lifted their price target on shares of Protagonist Therapeutics from $102.00 to $112.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Protagonist Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $107.31.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.